Physician profile
Adaani Frost
NPI 1740360098
$17,841.28
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,644 · 2021: $19.41.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals, Ltd | $8,664.13 | 2019-2020 | |
| Vectura Limited | $6,566.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $1,354.73 | 2019 | |
| Gilead Sciences, INC. | $1,051.02 | 2019 | |
| United Therapeutics Corporation | $111.74 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.25 | 2019 | |
| Ambu INC. | $19.41 | 2021 |
Research and ownership
$31,390.75 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adaani Frost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.